{
    "nctId": "NCT03927456",
    "briefTitle": "A Study of SHR6390 in Combination With Fulvestrant in Patients With HR Positive and HER2 Negative Advanced Breast Cancer",
    "officialTitle": "A Phase III Study to Evaluate the Efficacy and Safety of SHR6390 in Combination With Fulvestrant Versus Placebo Combined With Fulvesrant in Patients With HR Positive and HER2 Negative Recurrent/Metastatic Breast Cancer",
    "overallStatus": "UNKNOWN",
    "conditions": "Advanced Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE3",
    "allocation": "RANDOMIZED",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 357,
    "primaryOutcomeMeasure": "Investigator-assessed PFS",
    "eligibilityCriteria": "Inclusion Criteria:\n\n1. Has the pathologically-confirmed diagnosis of locally recurrent or metastatic, hormone-receptor positive, HER2 negative Breast Cancer.\n2. Age: 18 - 75 years old, postmenopausal women or prepostmenopausal women\n3. Received prior endocrine therapy\n4. One previous line of chemotherapy for advanced/metastatic disease is allowed in addition to endocrine therapy.\n5. Eastern Cooperative Oncology Group \\[ECOG\\] 0-1\n\nExclusion Criteria:\n\n1. Patients who received prior treatment with any CDK4/6 inhibitor, everolimus or fulvestant.\n2. Clinically significant cardiovascular and cerebrovascular diseases,including but not limited to severe acute myocardial infarction within 6 months before enrollment, unstable or severe angina, Congestive heart failure (New York heart association (NYHA) class \\> 2), or ventricular arrhythmia which need medical intervention.",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}